ischemic cardiomyopathy
-
Hemostemix Plans to Revolutionize Stem Cell Therapy with Scalable Production and New Sales Goals
Hemostemix Inc. (TSXV: HEM | OTCQB: HMTXF | FSE: 2VF0) has developed an effective “stem cell therapy” for…
-
Hemostemix adds depth and strength to its scientific bench on the road to commercialization
Since we last covered Hemostemix where they released the promising results of their retrospective study of heart disease…
-
Thomas Smeenk of Hemostemix talks about market reaction to successful litigation settlement
In this InvestorIntel interview with host Stephen Lautens, Hemostemix Inc.’s (TSXV: HEM | OTCQB: HMTXF) Co-Founder, President and…
-
Hemostemix’s stem cell therapy pursues ‘Your Fountain of Youth’
What’s a company worth to investors that could improve numerous medical conditions related to ischemia (lack of blood…
-
Revolutionizing the way we treat lack of blood flow diseases by using stem cell therapy
Every year modern medicine makes new breakthroughs that continue to amaze. Today’s company has a breakthrough ‘stem cell…
